Hiroyuki Takase1, Yasuaki Dohi2, Hiroo Sonoda2, Genjiro Kimura2. 1. Department of Internal Medicine, Enshu Hospital, Hamamatsu, Japan. 2. Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Abstract
Background: Although several conditions have been proposed as risk factors contributing to the incidence of atrial fibrillation, many individuals without such 'risk factors' also suffer from atrial fibrillation. The present study tested the hypothesis that the risk of new-onset atrial fibrillation increases with increasing circulating levels of B-type natriuretic peptide in the general population. Methods: Participants in our health checkup program without atrial fibrillation or a history of atrial fibrillation were enrolled (n=10,058, 54.3±11.3 years old). After baseline evaluation, subjects were followed up for the median of 1,791 days with the endpoint being the new onset of atrial fibrillation. Results: Atrial fibrillation occurred in 53 subjects during the follow-up period (1.16 per 1,000 person-year). The risk of new-onset atrial fibrillation increased across the gender-specific quartiles of B-type natriuretic peptide levels at baseline. In multivariate Cox proportional hazard regression analysis where B-type natriuretic peptide concentrations were taken as a continuous variable, B-type natriuretic peptide was a significant predictor of new onset of atrial fibrillation after adjustment for possible factors (hazard ratio 5.65 [95% CI 2.63-12.41]). Conclusions: The risk of new onset of atrial fibrillation increases with increasing B-type natriuretic peptide levels in the general population. Measurement of B-type natriuretic peptide may improve the prediction of incident atrial fibrillation.
Background: Although several conditions have been proposed as risk factors contributing to the incidence of atrial fibrillation, many individuals without such 'risk factors' also suffer from atrial fibrillation. The present study tested the hypothesis that the risk of new-onset atrial fibrillation increases with increasing circulating levels of B-type natriuretic peptide in the general population. Methods:Participants in our health checkup program without atrial fibrillation or a history of atrial fibrillation were enrolled (n=10,058, 54.3±11.3 years old). After baseline evaluation, subjects were followed up for the median of 1,791 days with the endpoint being the new onset of atrial fibrillation. Results:Atrial fibrillation occurred in 53 subjects during the follow-up period (1.16 per 1,000 person-year). The risk of new-onset atrial fibrillation increased across the gender-specific quartiles of B-type natriuretic peptide levels at baseline. In multivariate Cox proportional hazard regression analysis where B-type natriuretic peptide concentrations were taken as a continuous variable, B-type natriuretic peptide was a significant predictor of new onset of atrial fibrillation after adjustment for possible factors (hazard ratio 5.65 [95% CI 2.63-12.41]). Conclusions: The risk of new onset of atrial fibrillation increases with increasing B-type natriuretic peptide levels in the general population. Measurement of B-type natriuretic peptide may improve the prediction of incident atrial fibrillation.
Authors: Y Hirata; A Matsumoto; T Aoyagi; K Yamaoki; I Komuro; T Suzuki; T Ashida; T Sugiyama; Y Hada; I Kuwajima; M Nishinaga; H Akioka; O Nakajima; R Nagai; Y Yazaki Journal: Cardiovasc Res Date: 2001-08-15 Impact factor: 10.787
Authors: H Takase; T Toriyama; T Sugiura; A Takahashi; M Sugiyama; M Ohashi; R Ueda; Y Dohi Journal: Eur J Clin Invest Date: 2007-04 Impact factor: 4.686
Authors: Wojciech Szczeklik; Yannick LeManach; Jakub Fronczek; Kamil Polok; David Conen; Finlay A McAlister; Sadeesh Srinathan; Pablo Alonso-Coello; Bruce Biccard; Emmanuelle Duceppe; Diane Heels-Ansdell; Jacek Górka; Shirley Pettit; Pavel S Roshanov; P J Devereaux Journal: CMAJ Date: 2020-12-07 Impact factor: 8.262